China SXT Pharmaceuticals sinks 88% after $12 million direct offering announcement

Shares of China SXT Pharmaceuticals plunged after the company announced a $12 million registered direct offering that outlets said carries significant dilution potential. Additional reports flagged extreme volatility, a terminated offshore deal, and a zero-price warrant option that could add shares.